CHARLOTTE — A new weight-loss drug from Eli Lilly could be one step closer to reaching the market after late-stage clinical trial results showed promising outcomes.
[ ALSO READ: Medicare is now covering some GLP-1 weight loss drugs for $50. Here’s what to know ]
The company said participants taking its experimental drug, retatrutide, lost an average of about 50 pounds over 18 months during the study.
The medication works by targeting three hormones involved in appetite and metabolism, a different approach than many existing weight-loss treatments.
The most commonly reported side effects were stomach-related.
Retatrutide is currently under review by the U.S. Food and Drug Administration, with a decision possible as early as 2027.